NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI 3 trial. [PDF]
Macarulla T +19 more
europepmc +1 more source
Preoperative Chemoradiotherapy with Tegafur-Uracil, Capecitabine, or 5-Fluorouracil/Leucovorin for Rectal Cancer in an Asian Cohort: A Real-World Comparison from the Pre-TNT Era. [PDF]
Dai KY, Chen FY, Liu CK, Lin J, Liu SH.
europepmc +1 more source
Vascular Dysfunction in Colorectal Cancer: Scoping Review of Current Evidence for Guiding Future Research. [PDF]
DeJonge SR +4 more
europepmc +1 more source
NALIRIFOX versus gemcitabine plus nab-paclitaxel in Chinese patients with advanced pancreatic adenocarcinoma: a randomized, open-label phase II trial. [PDF]
Gao C +35 more
europepmc +1 more source
Case Report: long complete metabolic response assessed by LAFOV FDG-PET/CT to FOLFIRINOX in first-line treatment of metastatic low-differentiated pancreatic carcinoma. [PDF]
Abgral R +3 more
europepmc +1 more source
Body mass index has no impact on complications and mortality for patients with stage IV pancreatic ductal adenocarcinoma. [PDF]
Bryant R +5 more
europepmc +1 more source
Three Versus 6 Months of Adjuvant Oxaliplatin-Fluoropyrimidine Chemotherapy for Colorectal Cancer: Final Results of SCOT-An International, Randomized, Phase III, Noninferiority Trial. [PDF]
Iveson T +31 more
europepmc +1 more source
A case of systemic toxicity after intralesional methotrexate for non-melanoma skin cancer in a patient with chronic kidney disease. [PDF]
Lamberg O, Powers JG, Negbenebor NA.
europepmc +1 more source
Defining the Prognostic Significance of BRAF V600E in Early-Stage Colon Cancer: A Systematic Review and Meta-Analysis. [PDF]
Dankner M +12 more
europepmc +1 more source

